Related Experiment Video
Updated: Oct 30, 2025
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
18.1K
Innovative Trials and New Opportunities in SLE
Yashaar Chaichian1, Daniel J Wallace2
1Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA.
Rheumatic Diseases Clinics of North America
|July 3, 2021
Summary
Systemic lupus erythematosus (SLE) treatments show limited success, but new therapeutic strategies and optimized existing treatments offer hope for improved patient outcomes and quality of life.
Area of Science:
- Immunology
- Rheumatology
- Clinical Medicine
Background:
- Systemic lupus erythematosus (SLE) remains a challenging autoimmune disease with low remission rates.
- Current treatments for SLE have limitations in efficacy and impact on quality of life.
Purpose of the Study:
- To review recent advances in SLE treatment strategies.
- To discuss the optimal use of existing therapies for SLE.
- To highlight emerging insights into SLE pathogenesis.
Main Methods:
- Review of recent clinical studies and therapeutic strategies for SLE.
- Analysis of emerging data on SLE disease mechanisms.
- Evaluation of studies on optimizing current SLE treatments.
Main Results:
- Novel therapeutic strategies show promise based on new understandings of SLE.
- Optimizing existing treatments can improve efficacy and reduce toxicity in SLE patients.
- Recent research offers potential for better SLE management.
Conclusions:
- Despite challenges, advancements in understanding SLE mechanisms are paving the way for more effective treatments.
- Improved therapeutic approaches and optimized existing treatments may lead to better outcomes for SLE patients.
- Further research is crucial to unlock the key to satisfactory SLE treatment.
Related Concept Videos
01:11Clinical Trials: Overview
4.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.0K
01:16Clinical Trials
9.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
9.9K
01:26Nephrotic Syndrome II : Assessment and Medical Management
47
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
47
01:24Nephrotic Syndrome I : Introduction
223
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
223
01:21EPS and iPS Cells in Disease Research
3.1K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.1K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
270
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
270